Abstract:Primary liver cancer, which is scientifically referred to as hepatocellular carcinoma (HCC), is a significant concern in the field of global health. It has been demonstrated that conventional chemotherapy, chemo-hormonal therapy, and conformal radiotherapy are ineffective against HCC. New therapeutic approaches are thus urgently required. Identifying single or multiple mutations in genes associated with invasion, metastasis, apoptosis, and growth regulation has resulted in a more comprehensive comprehension of the molecular genetic underpinnings of malignant transformation, tumor advancement, and host interaction. This enhanced comprehension has notably propelled the development of novel therapeutic agents. Therefore, gene therapy (GT) holds great promise for addressing the urgent need for innovative treatments in HCC. However, the complexity of HCC demands precise and effective therapeutic approaches. The adeno-associated virus (AAV) distinctive life cycle and ability to persistently infect dividing and nondividing cells have rendered it an alluring vector. Another appealing characteristic of the wild-type virus is its evident absence of pathogenicity. As a result, AAV, a vector that lacks an envelope and can be modified to transport DNA to specific cells, has garnered considerable interest in the scientific community, particularly in experimental therapeutic strategies that are still in the clinical stage. AAV vectors emerge as promising tools for HCC therapy due to their non-immunogenic nature, efficient cell entry, and prolonged gene expression. While AAV-mediated GT demonstrates promise across diverse diseases, the current absence of ongoing clinical trials targeting HCC underscores untapped potential in this context. Furthermore, gene transfer through hepatic AAV vectors is frequently facilitated by GT research, which has been propelled by several congenital anomalies affecting the liver. Notwithstanding the enthusiasm associated with this notion, recent discoveries that expose the integration of the AAV vector genome at double-strand breaks give rise to apprehensions regarding their enduring safety and effectiveness. This review explores the potential of AAV vectors as versatile tools for targeted GT in HCC. In summation, we encapsulate the multifaceted exploration of AAV vectors in HCC GT, underlining their transformative potential within the landscape of oncology and human health.

Adeno-Associated Virus Gene Therapy for Liver Disease

Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders

Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Advancing Liver Gene Therapy: Enhanced Transduction with GalNAc-Bioconjugated rAAV Capsids

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.

Adeno-associated virus vector as a platform for gene therapy delivery

Engineering adeno-associated virus vectors for gene therapy

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Directed evolution of adeno-associated virus 5 capsid enables specific liver tropism

Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Various AAV Serotypes and Their Applications in Gene Therapy: An Overview

The clinical landscape for AAV gene therapies

AAV-based in vivo gene therapy for neurological disorders

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges